Bausch Health Companies Inc.BHC
ASignal's systematic analysis rates BHC as Neutral. Bausch Health Companies Inc. has a market cap of $2.58B, a -10.1% net margin, and 12.7% year-over-year revenue growth.
Reflects the latest available analysis · analyzed Aug 3, 2026
The case on BHC
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (12.7% YoY)
- High gross margin (71.82%) indicating pricing power
- Positive free cash flow ($1.43B)
- Earnings growth accelerating (70.4% YoY)
- Low forward P/E ratio (1.71x) suggesting deep value
- RSI at 80.72 indicating overbought conditions
- Price trading significantly above Bollinger Bands (current price $6.89 vs upper band $6.05)
- Negative price-to-book ratio (-1.25x), signaling potential balance sheet concerns
- Negative net margin (-10.12%) despite strong operating margin
- No Reddit mentions, suggesting lack of retail interest or visibility
Key facts
See the full verdict on BHC
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes BHC
Most investors never get a second opinion, let alone several. ASignal runs BHC past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.